journal article·2026-12-31Open access

Folate receptor-targeted PEGylated PLGA nanoparticles for the site-specific delivery of hesperidin in epithelial ovarian cancer

Rohini Kharwade, Nilesh M. Mahajan, Darshan R. Telange, Priyanka N. Yadav, Sachin R. More

Abstract

Hesperidin (HSP) is a polyphenolic compound employed widely in the therapy of epithelial ovarian cancer (EOC). However, the low bioavailability, attributed to first-pass metabolism, low dissolution and poor tumour specificity, hampered its clinical effectiveness. Therefore, HSP-loaded folic acid-PEGylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (HSP-PEGylated PLGA FA NPs) were synthesized to improve dissolution and target specificity of HSP for the management of EOC. The NPs were synthesized by nanoprecipitation and assessed for entrapment efficiency, particle size, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD) and in vitro dissolution. Additionally, antioxidant assay, cytotoxicity, cellular uptake and flow cytometric were performed on folate receptor overexpressing SKOV3 cell line. Physico-chemical characterization supported the formation of HSP-PEGylated PLGA FA NPs with entrapment efficiency ∼89.34%, particle size ∼205 nm, and a zeta potential of ∼ -25 mV, demonstrating their physical stability. The NPs enhanced HSP release at pH 5.5 compared to pH 7.4. The NPs showed greater cytotoxicity at an IC50 value of ∼29 µM/mL and enhanced early apoptosis ∼44% as compared to HSP-PEGylated PLGA NPs ∼32% towards the FA receptor overexpressed EOC cell line. The developed formulation shows promising potential as a targeted NP system for the management of EOC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Dadasaheb Balpande College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University

Adjunct faculty, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, Sawangi (Meghe)

Datta Meghe Institute of Higher Education and Research (DU), Sawangi (Meghe)

Funding

Rashtrasant Tukadoji Maharaj Nagpur University

References (91)

Show source-provided references
1. 10.15419/bmrat.v4i12.38610.15419/bmrat.v4i12.386 ↗
2. 10.1016/j.ajhg.2011.11.01610.1016/j.ajhg.2011.11.016 ↗
3. 10.1007/s10734-006-9019-310.1007/s10734-006-9019-3 ↗
4. 10.1155/2007/30938210.1155/2007/309382 ↗
5. 10.3390/antiox1104066310.3390/antiox11040663 ↗
6. 10.3322/caac.2149210.3322/caac.21492 ↗
7. 10.3322/caac.2183410.3322/caac.21834 ↗
8. 10.3390/ijms2410893010.3390/ijms24108930 ↗
9. Caan BJ, Thomson CA. Breast and ovarian cancer. Optimizing women’s health through nutrition. Boca Raton (FL): CRCPress;.2007. p. 229–263.
10. 10.3390/molecules2719648810.3390/molecules27196488 ↗
11. 10.1007/s13346-024-01698-410.1007/s13346-024-01698-4 ↗
12. 10.1007/s13346-024-01649-z10.1007/s13346-024-01649-z ↗
13. 10.3906/sag-1912-20910.3906/sag-1912-209 ↗
14. 10.1007/s11051-017-4076-310.1007/s11051-017-4076-3 ↗
15. 10.1007/s42399-020-00528-110.1007/s42399-020-00528-1 ↗
16. 10.1038/s41598-020-66419-610.1038/s41598-020-66419-6 ↗
17. 10.1016/j.ipha.2024.09.00510.1016/j.ipha.2024.09.005 ↗
18. 10.1002/bab.240410.1002/bab.2404 ↗
19. 10.3389/fphar.2024.143379310.3389/fphar.2024.1433793 ↗
20. 10.1002/slct.20240386910.1002/slct.202403869 ↗
21. 10.1007/s12668-025-01829-210.1007/s12668-025-01829-2 ↗
22. 10.1016/j.addr.2019.01.00510.1016/j.addr.2019.01.005 ↗
23. 10.1021/acs.bioconjchem.9b0045610.1021/acs.bioconjchem.9b00456 ↗
24. 10.1016/j.bbiosy.2021.10002210.1016/j.bbiosy.2021.100022 ↗
25. 10.1002/pat.130410.1002/pat.1304 ↗
26. Kumar PD, Kumar PV, Selvam TP, et al. Prolonged drug delivery system of PEGylated PAMAM dendrimers with a anti-HIV drug. Res Pharm. 2013;3(2):8–17.
27. 10.3390/nano1203035410.3390/nano12030354 ↗
28. 10.1016/j.eurpolymj.2018.09.01110.1016/j.eurpolymj.2018.09.011 ↗
29. 10.2217/nnm-2016-031510.2217/nnm-2016-0315 ↗
30. 10.1016/j.colsurfb.2015.11.03310.1016/j.colsurfb.2015.11.033 ↗
31. 10.1021/acsomega.5c0291610.1021/acsomega.5c02916 ↗
32. Sawyer A, Saucier J, Nguyen JQD. 基因的改变NIH public access. Science (1979). 2011;23(1):1–7. (80).
33. 10.2147/IJN.S21032010.2147/IJN.S210320 ↗
34. 10.1080/21691401.2022.211875810.1080/21691401.2022.2118758 ↗
35. 10.3390/polym1212293010.3390/polym12122930 ↗
36. 10.1080/1061186X.2018.152341810.1080/1061186X.2018.1523418 ↗
37. 10.1016/j.toxlet.2005.10.00310.1016/j.toxlet.2005.10.003 ↗
38. 10.1080/21691401.2019.159384810.1080/21691401.2019.1593848 ↗
39. 10.2147/DDDT.S8132010.2147/DDDT.S81320 ↗
40. 10.3390/pharmaceutics171216131510.3390/pharmaceutics1712161315 ↗
41. 10.2147/DDDT.S10190010.2147/DDDT.S101900 ↗
42. Ben SS, Liu P, Shao FM, et al. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. Int J Clin Exp Med. 2015;8(10):19670–19681.
43. 10.3390/magnetochemistry901001210.3390/magnetochemistry9010012 ↗
44. 10.1049/iet-nbt.2019.028710.1049/iet-nbt.2019.0287 ↗
45. 10.3390/polym1201000510.3390/polym12010005 ↗
46. 10.1021/acsnano.9b0515710.1021/acsnano.9b05157 ↗
47. 10.1016/j.ijpharm.2020.11988710.1016/j.ijpharm.2020.119887 ↗
48. 10.1002/fsn3.356910.1002/fsn3.3569 ↗
49. 10.1016/j.chemphyslip.2021.10512310.1016/j.chemphyslip.2021.105123 ↗
50. 10.1016/j.colsurfb.2020.11122710.1016/j.colsurfb.2020.111227 ↗
51. 10.1016/j.bbagen.2013.10.00210.1016/j.bbagen.2013.10.002 ↗
52. 10.1007/s10620-020-06787-110.1007/s10620-020-06787-1 ↗
53. 10.3390/bios1204019610.3390/bios12040196 ↗
54. 10.1080/10837450.2023.217323010.1080/10837450.2023.2173230 ↗
55. 10.1016/j.jsps.2024.10215410.1016/j.jsps.2024.102154 ↗
56. Park J Ha MK Yang N et al. Flow cytometry –based quantification of cellular au nanoparticles. Analytical Chemistry. 2017;89(4):2449–2456. doi: 10.1021/acs.analchem.6b04418.10.1021/acs.analchem.6b04418 ↗
57. Atluri VSR Jayant RD Pilakka-Kanthikeel S et al. Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection.2016;31(11):4287–4298. doi: 10.2147/IJN.S108329.10.2147/IJN.S108329 ↗
58. 10.1016/j.ijpharm.2021.12098610.1016/j.ijpharm.2021.120986 ↗
59. 10.1016/j.ejps.2021.10591610.1016/j.ejps.2021.105916 ↗
60. 10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F ↗
61. 10.7508/nmrj.2016.02.00110.7508/nmrj.2016.02.001 ↗
62. 10.1016/j.msec.2017.03.13010.1016/j.msec.2017.03.130 ↗
63. 10.1016/j.addr.2009.11.02110.1016/j.addr.2009.11.021 ↗
64. 10.5681/bi.2013.01610.5681/bi.2013.016 ↗
65. 10.3390/pharmaceutics1204036310.3390/pharmaceutics12040363 ↗
66. 10.2147/IJN.S3801310.2147/IJN.S38013 ↗
67. 10.21741/9781644903353-1310.21741/9781644903353-13 ↗
68. Paarakh MP, Jose PANI, Setty CM, et al. Release kinetics – concepts and applications. Int J Pharm Res Technol. 2019;8(1):12–20.
69. 10.1186/s12929-019-0592-z10.1186/s12929-019-0592-z ↗
70. 10.1007/s13346-025-01884-y10.1007/s13346-025-01884-y ↗
71. 10.1016/j.jddst.2021.10282210.1016/j.jddst.2021.102822 ↗
72. 10.3109/17435390.2010.51684410.3109/17435390.2010.516844 ↗
73. 10.1166/jnn.2014.799510.1166/jnn.2014.7995 ↗
74. 10.5937/vojtehg67-1825110.5937/vojtehg67-18251 ↗
75. 10.3390/ijms2307400010.3390/ijms23074000 ↗
76. 10.3390/ijms2409796310.3390/ijms24097963 ↗
77. 10.1208/s12249-022-02315-810.1208/s12249-022-02315-8 ↗
78. Upadhyay P, Upadhyay S. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. J Appl Pharm Sci. 2011;1(6):186–190.
79. 10.1007/s40005-019-00439-x10.1007/s40005-019-00439-x ↗
80. 10.1016/0168-3659(93)90218-T10.1016/0168-3659(93)90218-T ↗
81. 10.2147/IJN.S49902410.2147/IJN.S499024 ↗
82. 10.2217/17435889.2.6.78910.2217/17435889.2.6.789 ↗
83. 10.2174/157341371666620021311483610.2174/1573413716666200213114836 ↗
84. 10.1016/s0891-5849(01)00543-310.1016/s0891-5849(01)00543-3 ↗
85. 10.7508/ibj.2016.01.00110.7508/ibj.2016.01.001 ↗
86. 10.3109/0363904100378619310.3109/03639041003786193 ↗
87. 10.1016/j.heliyon.2023.e2122710.1016/j.heliyon.2023.e21227 ↗
88. 10.1016/j.ijpharm.2018.08.01610.1016/j.ijpharm.2018.08.016 ↗
89. 10.1186/s12885-020-06803-710.1186/s12885-020-06803-7 ↗
90. 10.1101/pdb.prot09549710.1101/pdb.prot095497 ↗
91. 10.1016/S0142-9612(02)00445-310.1016/S0142-9612(02)00445-3 ↗